JDQ443 chemical structure, oral KRAS(G12C) inhibitor (Novartis, Basel, CH)

oral KRAS(G12C) inhibitor

ph. III candidate for NSCLC

from de novo SBDD in SWII pocket

Cancer Discov.

Novartis, Basel, CH

Context. JDQ443 (Novartis Institute for Biomedical Research) is an oral KRASG12C inhibitor being developed for various advanced solid tumors. Despite accounting for 85% of RAS oncogenic mutations in all…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.